AI assistant
BridgeBio Pharma, Inc. — Director's Dealing 2025
Aug 12, 2025
30604_dirs_2025-08-11_eb69da73-f812-469a-a1c7-4315279f0ff9.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2025-08-07
Reporting Person: Kumar Neil (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-08-07 | Common Stock | S | 6784 | $45.0927 | Disposed | 4751663 | Indirect |
| 2025-08-07 | Common Stock | S | 13216 | $45.638 | Disposed | 4738447 | Indirect |
| 2025-08-08 | Common Stock | S | 11795 | $45.8806 | Disposed | 4726652 | Indirect |
| 2025-08-08 | Common Stock | S | 8205 | $46.7096 | Disposed | 4718447 | Indirect |
| 2025-08-07 | Common Stock | S | 6784 | $45.0927 | Disposed | 948902 | Indirect |
| 2025-08-07 | Common Stock | S | 13216 | $45.638 | Disposed | 935686 | Indirect |
| 2025-08-08 | Common Stock | S | 11795 | $45.8806 | Disposed | 923891 | Indirect |
| 2025-08-08 | Common Stock | S | 8205 | $46.7096 | Disposed | 915686 | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 217404 | Direct |
Footnotes
F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.
F2: Represents the weighted average sale price of the shares sold from $44.31 to $45.305 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
F3: Represents the weighted average sale price of the shares sold from $45.31 to $46.10 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
F4: Represents the weighted average sale price of the shares sold from $45.49 to $46.48 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
F5: Represents the weighted average sale price of the shares sold from $46.49 to $47.20 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.